VR Logo

Ginkgo Bioworks Holdings Inc. Class A (DNA) download report


Healthcare | Biotechnology & Pharma Research

Ginkgo Bioworks Holdings Inc. Class A (DNA) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming.

IPO Date: 19-Apr-2021

Co-Founder, CEO & Director: Dr. Jason Kelly

Co-Founder, Pres, COO & Director: Dr. Reshma P. Shetty

Listing: NYSE: DNA

Country: United States

Headquarters: Boston, MA

Website: https://www.ginkgobioworks.com

Key Facts

Market cap: $4,637.03 Mln

Revenue (TTM): $482.24 Mln

Earnings (TTM): $-2,399.80 Mln

Cash: $1,492.97 Mln

Total Debt: $27.31 Mln

Insider's Holding: 9.41%

Liquidity: Low

52 Week range: $2.09 - 15.86

Shares outstanding: 1,093,520,000

Stock Performance

Time Period Ginkgo Bioworks Holdings Inc. Class A (DNA) S&P BSE Sensex S&P Small-Cap 600
YTD-70.46-8.99-19.23
1 month-23.52-3.40-9.35
3 months-46.51-8.50-16.59
1 Year-75.400.89-17.36
3 Years--10.415.90
5 Years--11.435.77
10 Years--11.779.78
As on 30-Jun-2022